Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Br J Surg ; 111(2)2024 Jan 31.
Article in English | MEDLINE | ID: mdl-38387083

ABSTRACT

BACKGROUND: This study evaluated the association of pathological tumour response (tumour regression grade, TRG) and a novel scoring system, combining both TRG and nodal status (TRG-ypN score; TRG1-ypN0, TRG>1-ypN0, TRG1-ypN+ and TRG>1-ypN+), with recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. METHODS: This Dutch nationwide cohort study included patients treated with neoadjuvant chemoradiotherapy followed by oesophagectomy for distal oesophageal or gastro-oesophageal junctional adenocarcinoma between 2007 and 2016. The primary endpoint was the association of Mandard score and TRG-ypN score with recurrence patterns (rate, location, and time to recurrence). The secondary endpoint was overall survival. RESULTS: Among 2746 inclusions, recurrence rates increased with higher Mandard scores (TRG1 30.6%, TRG2 44.9%, TRG3 52.9%, TRG4 61.4%, TRG5 58.2%; P < 0.001). Among patients with recurrent disease, the distribution (locoregional versus distant) was the same for the different TRG groups. Patients with TRG1 developed more brain recurrences (17.7 versus 9.8%; P = 0.001) and had a longer mean overall survival (44 versus 35 months; P < 0.001) than those with TRG>1. The TRG>1-ypN+ group had the highest recurrence rate (64.9%) and worst overall survival (mean 27 months). Compared with the TRG>1-ypN0 group, patients with TRG1-ypN+ had a higher risk of recurrence (51.9 versus 39.6%; P < 0.001) and worse mean overall survival (33 versus 41 months; P < 0.001). CONCLUSION: Improved tumour response to neoadjuvant therapy was associated with lower recurrence rates and higher overall survival rates. Among patients with recurrent disease, TRG1 was associated with a higher incidence of brain recurrence than TRG>1. Residual nodal disease influenced prognosis more negatively than residual disease at the primary tumour site.


Subject(s)
Adenocarcinoma , Esophageal Neoplasms , Humans , Prognosis , Cohort Studies , Disease-Free Survival , Combined Modality Therapy
3.
Ann Surg ; 277(4): 619-628, 2023 04 01.
Article in English | MEDLINE | ID: mdl-35129488

ABSTRACT

OBJECTIVE: This study evaluated the nationwide trends in care and accompanied postoperative outcomes for patients with distal esophageal and gastro-esophageal junction cancer. SUMMARY OF BACKGROUND DATA: The introduction of transthoracic esophagectomy, minimally invasive surgery, and neo-adjuvant chemo(radio)therapy changed care for patients with esophageal cancer. METHODS: Patients after elective transthoracic and transhiatal esophagectomy for distal esophageal or gastroesophageal junction carcinoma in the Netherlands between 2007-2016 were included. The primary aim was to evaluate trends in both care and postoperative outcomes for the included patients. Additionally, postoperative outcomes after transthoracic and tran-shiatal esophagectomy were compared, stratified by time periods. RESULTS: Among 4712 patients included, 74% had distal esophageal tumors and 87% had adenocarcinomas. Between 2007 and 2016, the proportion of transthoracic esophagectomy increased from 41% to 81%, and neo-adjuvant treatment and minimally invasive esophagectomy increased from 31% to 96%, and from 7% to 80%, respectively. Over this 10-year period, postoperative outcomes improved: postoperative morbidity decreased from 66.6% to 61.8% ( P = 0.001), R0 resection rate increased from 90.0% to 96.5% (P <0.001), median lymph node harvest increased from 15 to 19 ( P <0.001), and median survival increased from 35 to 41 months ( P = 0.027). CONCLUSION: In this nationwide cohort, a transition towards more neo-adju-vant treatment, transthoracic esophagectomy and minimally invasive surgery was observed over a 10-year period, accompanied by decreased postoperative morbidity, improved surgical radicality and lymph node harvest, and improved survival.


Subject(s)
Adenocarcinoma , Esophageal Neoplasms , Stomach Neoplasms , Humans , Adenocarcinoma/surgery , Lymph Nodes/pathology , Esophagogastric Junction/surgery , Esophagogastric Junction/pathology , Lymph Node Excision , Esophageal Neoplasms/surgery , Esophagectomy/adverse effects , Stomach Neoplasms/surgery , Postoperative Complications/etiology , Treatment Outcome
4.
Ann Surg ; 276(5): 806-813, 2022 11 01.
Article in English | MEDLINE | ID: mdl-35880759

ABSTRACT

OBJECTIVE: This study investigated the patterns, predictors, and survival of recurrent disease following esophageal cancer surgery. BACKGROUND: Survival of recurrent esophageal cancer is usually poor, with limited prospects of remission. METHODS: This nationwide cohort study included patients with distal esophageal and gastroesophageal junction adenocarcinoma and squamous cell carcinoma after curatively intended esophagectomy in 2007 to 2016 (follow-up until January 2020). Patients with distant metastases detected during surgery were excluded. Univariable and multivariable logistic regression were used to identify predictors of recurrent disease. Multivariable Cox regression was used to determine the association of recurrence site and treatment intent with postrecurrence survival. RESULTS: Among 4626 patients, 45.1% developed recurrent disease a median of 11 months postoperative, of whom most had solely distant metastases (59.8%). Disease recurrences were most frequently hepatic (26.2%) or pulmonary (25.1%). Factors significantly associated with disease recurrence included young age (≤65 y), male sex, adenocarcinoma, open surgery, transthoracic esophagectomy, nonradical resection, higher T-stage, and tumor positive lymph nodes. Overall, median postrecurrence survival was 4 months [95% confidence interval (95% CI): 3.6-4.4]. After curatively intended recurrence treatment, median survival was 20 months (95% CI: 16.4-23.7). Survival was more favorable after locoregional compared with distant recurrence (hazard ratio: 0.74, 95% CI: 0.65-0.84). CONCLUSIONS: This study provides important prognostic information assisting in the surveillance and counseling of patients after curatively intended esophageal cancer surgery. Nearly half the patients developed recurrent disease, with limited prospects of survival. The risk of recurrence was higher in patients with a higher tumor stage, nonradical resection and positive lymph node harvest.


Subject(s)
Adenocarcinoma , Esophageal Neoplasms , Adenocarcinoma/pathology , Cohort Studies , Esophagectomy , Humans , Lymphatic Metastasis , Male , Neoplasm Recurrence, Local/pathology , Prognosis , Retrospective Studies , Survival Rate
5.
BMC Cancer ; 17(1): 552, 2017 Aug 18.
Article in English | MEDLINE | ID: mdl-28821284

ABSTRACT

BACKGROUND: Following esophagectomy, esophageal cancer patients experience a clinically relevant deterioration of health-related quality of life, both on the short- and long-term. With the currently growing number of esophageal cancer survivors, the burden of disease- and treatment-related complaints and symptoms becomes more relevant. This emphasizes the need for interventions aimed at improving quality of life. Beneficial effects of post-operative physical exercise have been reported in several cancer types, but so far comparable evidence in esophageal cancer patients is lacking. The aim of this study is to investigate effects of physical exercise on health-related quality of life in esophageal cancer patients following surgery. METHODS: The Physical ExeRcise Following Esophageal Cancer Treatment (PERFECT) study is a multicenter randomized controlled trial including 150 esophageal cancer patients after surgery with curative intent. Patients are randomly allocated to an exercise group or usual care group. The exercise group participates in a 12-week combined aerobic and resistance exercise program, supervised by a physiotherapist near the patient's home-address. In addition, participants in the exercise group are requested to be physically active for at least 30 min per day, every day of the week. Participants allocated to the usual care group are asked to maintain their habitual physical activity pattern. The primary outcome is health-related quality of life (EORTC-QLQ-C30). Secondary outcomes include esophageal cancer specific quality of life, fatigue, anxiety and depression, sleep quality, work-related factors, cardiorespiratory fitness (VO2peak), muscle strength, physical activity, malnutrition risk, anthropometry, blood markers, recurrence of disease and survival. All questionnaire outcomes, diaries and accelerometers are assessed at baseline, post-intervention (12 weeks post-baseline) and 24 weeks post-baseline. Physical fitness, anthropometry and blood markers are assessed at baseline and post-intervention. In addition, adherence and safety are monitored throughout the exercise program. DISCUSSION: This randomized controlled trial investigates effects of physical exercise versus usual care in esophageal cancer patients after surgery. As the design of the exercise program closely resembles daily practice, this study can contribute both to evidence on effects of exercise in esophageal cancer patients, and to potential implementation strategies. TRIAL REGISTRATION: Trial registration:Netherlands Trial Registry NTR5045 Date of trial registration: January 19th, 2015 Date and version study protocol: February 2017, version 1.


Subject(s)
Clinical Protocols , Esophageal Neoplasms/rehabilitation , Exercise Therapy , Exercise , Postoperative Care , Esophageal Neoplasms/surgery , Exercise Therapy/methods , Humans , Quality of Life , Research Design , Resistance Training , Treatment Outcome
7.
Int J Colorectal Dis ; 24(8): 923-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19488771

ABSTRACT

OBJECTIVE: The aim of this study was to review the results and long-term outcome after total mesorectal excision (TME) for adenocarcinoma of the rectum in an unselected population in a community teaching hospital. MATERIALS AND METHODS: Between 1996 and 2003, 210 patients with rectal cancer were identified in our prospective database, containing patient characteristics, radiotherapy plans, operation notes, histopathological reports, and follow-up details. An evaluation of prognostic factors for local recurrence, distant metastases, and overall survival was performed. RESULTS: The mean age at diagnosis was 69 years (range 40-91 years). A total of 145 patients were treated by anterior rectal resection; 65 patients had to undergo an abdominoperineal resection (APR). Anastomotic leakage rate was 5%. Postoperative mortality was 3%. After a median follow-up of 3.6 years, the local recurrence-free rate in patients with microscopically complete resections was 91%. The 5-year overall survival rate was 58%. An increased serum carcinoembryonic antigen, an APR, positive lymph nodes, and an incomplete resection all significantly influenced the 5-year overall survival and local recurrence rate. In a multivariate analysis, age was the most important prognostic factor for overall survival. CONCLUSIONS: Patients with rectal cancer can safely be treated with TME in a community teaching hospital and leads to a good overall survival and an excellent local control. In patients aged above 80, treatment-related mortality is an important competitive risk factor, which obscures the positive effect of modern rectal cancer treatment.


Subject(s)
Adenocarcinoma/surgery , Digestive System Surgical Procedures , Outcome and Process Assessment, Health Care , Quality of Health Care , Rectal Neoplasms/surgery , Workload , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adult , Age Factors , Aged , Aged, 80 and over , Databases as Topic , Digestive System Surgical Procedures/adverse effects , Digestive System Surgical Procedures/mortality , Digestive System Surgical Procedures/statistics & numerical data , Disease-Free Survival , Feasibility Studies , Hospitals, Community/statistics & numerical data , Hospitals, Teaching/statistics & numerical data , Humans , Kaplan-Meier Estimate , Middle Aged , Neoplasm Recurrence, Local , Outcome and Process Assessment, Health Care/statistics & numerical data , Proportional Hazards Models , Quality of Health Care/statistics & numerical data , Rectal Neoplasms/mortality , Rectal Neoplasms/pathology , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Workload/statistics & numerical data
8.
World J Surg ; 26(3): 285-9, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11865362

ABSTRACT

Results and experience with the treatment of non-palpable breast cancer are reported and related to the future of less invasive treatment of small breast cancers. The retrospective study included 102 patients treated between 1980 and 1993 at the University Hospital of Nijmegen. Most cancers were screen-detected. Tumor sizes on pathological examination proved 3 mm (SD 7.7 mm) larger than on mammography (p = 0.0029). pT1 tumors were encountered in 77 patients (75%); pT2 tumors in 17 patients (17%). Seventy-five patients were free of lymph node metastases, 26 patients showed stage pN1 (25%). Most patients had invasive ductal cancers. Only two patients died of breast cancer. A 10-year disease-free survival of 94% was calculated, after excluding four patients with known systemic disease (M1) at diagnosis. T1a, T1b, and T1c had a 10-year survival of 100%, 96%, and 96%, respectively. Early detection and multimodality treatment of breast cancer have significantly improved survival. Inpatients with small breast cancer tumors future developments in treatment must be aimed at the use of less invasive techniques, reducing morbidity while maintaining high levels of disease-free survival.


Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/therapy , Outcome and Process Assessment, Health Care , Palpation , Adult , Aged , Breast Neoplasms/mortality , Carcinoma, Ductal, Breast/mortality , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Mastectomy , Middle Aged , Radiotherapy, Adjuvant , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...